$115 Million

TScan Therapeutics, Inc.

Initial Public Offering

Bookrunner, July 2021

TScan Therapeutics, Inc.

TScan Therapeutics, Inc. (“TScan” or the “Company”) is a preclinical-stage biopharmaceutical company focused on developing a robust pipeline of T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. Using one of its proprietary platform technologies, TargetScan, TScan analyzes the T cells of cancer patients with exceptional responses to immunotherapy to discover how the immune system naturally recognizes and eliminates tumor cells in these patients. TScan is also using its ReceptorScan technology to further diversify its portfolio of therapeutic TCRs. The Company is currently advancing a robust pipeline of TCR-T therapy candidates for the treatment of patients with hematologic and solid tumor malignancies.